COVID-19患者静脉-静脉体外膜氧合后六个月肺功能
这项回顾性观察性队列研究纳入2020年3月10日至4月30日期间两家ICU中所有接受VV-ECMO治疗的成人COVID-19幸存者。32例中11例(34%)成功脱机并出院回家,中位年龄56岁,机械通气和ECMO中位时间分别为26天和15天。中位178天后评估显示肺容积功能保留(FVC中位83%预计值,FEV1中位82%预计值),但DLCO中位58%预计值下降,6分钟步行试验中位468米。提示VV-ECMO幸存者长期肺容积功能良好但弥散功能受损。
要点
- 32例接受VV-ECMO的COVID-19患者中11例(34%)成功脱机出院,中位机械通气26天、ECMO 15天。
- 9例完成肺功能测试,中位FVC为83%预计值(51-99%),FEV1为82%预计值(60-99%),肺容积功能保留。
- DLCO中位58%预计值(37-95%)下降,6分钟步行试验中位468米(365-625米,对应63-90%预计值)。
- 评估在中位178天(范围72-232天)后进行,提示长期随访中弥散功能异常需关注。
适用人群与场景
- 成人COVID-19危重症幸存者,接受VV-ECMO治疗,来自两家三级(30床)和二级(22床)混合医学-外科ICU。
- 研究期间为2020年3月10日至4月30日。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 回顾性观察性队列,两家ICU,32例接受VV-ECMO的COVID-19患者中11例(34%)成功脱机出院;中位年龄56岁,机械通气中位26天,ECMO中位15天。
- 9例完成肺功能测试,中位FVC 83%预计值(51-99%),FEV1 82%预计值(60-99%),残气量100%预计值(50-140%),肺容量90%预计值(50-100%)。
- DLCO中位58%预计值(37-95%),6分钟步行试验中位468米(365-625米,对应63-90%预计值)。
证据类型、等级与局限
- 回顾性、观察性队列研究,样本量小(32例),仅11例出院,9例完成肺功能测试,单中心/双中心设计,存在选择偏倚和失访可能。
对床旁实践的改变
- 对于COVID-19接受VV-ECMO的幸存者,出院后随访应关注弥散功能(DLCO)和运动能力下降,即使肺容积功能保留。
- 不能根据本研究推断常规肺功能康复或药物干预的疗效,需个体化评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Venovenous extracorporeal membrane oxygenation has been largely used in patients with refractory acute respiratory distress syndrome due to coronavirus disease 2019. Few data on long-term pulmonary function among venovenous extracorporeal membrane oxygenation survivors are available.
DESIGN: Retrospective, observational cohort.
SETTING: Two mixed medical-surgical tertiary (30 beds) and secondary (22 beds) ICUs.
PATIENTS: All critically ill adult coronavirus disease 2019 survivors treated with venovenous extracorporeal membrane oxygenation between March 10, and April 30, 2020.
MEASUREMENTS AND MAIN RESULTS: The last available lung function and 6-minute walking tests, performed after a median of 178 days (ranges, 72-232 d) from ICU admission, were analyzed. Among the 32 coronavirus disease 2019 patients treated by venovenous extracorporeal membrane oxygenation during the study period, 11 (34%; median age 56 yr; median duration of mechanical ventilation and extracorporeal membrane oxygenation therapy of 26 and 15 d, respectively) were successfully weaned and discharged home. Spirometry was performed in nine patients; the volumetric lung function was preserved, that is, median forced vital capacity was 83% of predicted value (51-99% of predicted value), and median forced expiratory volume in 1 second was 82% of predicted value (60-99% of predicted value). Also, the median residual volume and the lung capacity were 100% of predicted value (50-140% of predicted value) and 90% of predicted value (50-100% of predicted value); only the diffusion capacity of the lung for carbon monoxide and 6-minute walking test were decreased (58% of predicted value [37-95% of predicted value] and 468 meters (365-625 meters), corresponding to [63-90% of predicted value], respectively).
CONCLUSIONS: Among survivors from severe coronavirus disease 2019 pneumonia treated with venovenous extracorporeal membrane oxygenation, preserved long-term volumetric lung function with decreased diffusion capacity of lung carbon monoxide was observed.
参考来源
- Ego A, Taton O, Brasseur A, et al. Six-Month Pulmonary Function After Venovenous Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 Patients. Crit Care Explor. 2021. PMID: 34291224. doi:10.1097/CCE.0000000000000494
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。